Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

Inclusion Criteria

• •Male or female aged 18 to 55 years (both inclusive).
• •Females must be surgically sterile, post-menopausal, or using reliable contraception and have negative pregnancy tests at screening and at Day -1.
• •A clinical diagnosis of schizophrenia or schizoaffective disorder and prescribed a stable dose of aripiprazole (10 to 30 mg/day), olanzapine (10 to 20 mg/day), paliperidone (3 to 12 mg/day), or risperidone (2 to 16 mg/day) for a minimum of 2 weeks before initial screening.
• •In good general health and expected to complete the clinical trial as designed.
• •Body Mass Index (BMI) of 18 kg/m\^2 to 38 kg/m\^2 (both inclusive) at screening.
• •Adequate hearing, vision, and language skills to perform the cognitive testing and other procedures specified in the protocol.
• •Voluntarily provided informed consent and signed an informed consent form (ICF) indicating that the purpose of the study was explained, and was willing and able to adhere to the study regimen and study procedures described in the ICF, including all confinement requirements.
• •Negative urine drug screen at screening and inpatient observation baseline period (Day -6), except for a short-acting benzodiazepine if prescribed for insomnia.
• •Fluent in English (speaking, writing, and reading).